BCAB Insider Trading Activity and SEC Form 4 Filings
BCAB insider trading summary
No open-market insider purchases or sales of BioAtla, Inc. (BCAB) have been reported on SEC Form 4 in the past 12 months.
Latest BCAB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 26, 2023 | Sylvia McBrinn | Director | Buy | $9K (4,000 @ $2.33) |
| Dec 20, 2023 | Jay M Phd Short | Chief Executive Officer | Buy | $107K (50,000 @ $2.14) |
| Dec 19, 2023 | Christian Vasquez | See Remarks | Buy | $15K (7,495 @ $2.04) |
| Dec 19, 2023 | Lawrence Steinman | Director | Buy | $41K (20,000 @ $2.05) |
| Sep 8, 2023 | Sylvia McBrinn | Director | Buy | $5K (2,000 @ $2.54) |
| Mar 29, 2023 | Jay M Phd Short | Chief Executive Officer | Buy | $101K (40,800 @ $2.47) |
| Mar 28, 2023 | Christian Vasquez | See Remarks | Buy | $48K (20,000 @ $2.40) |
| Mar 28, 2023 | Sylvia McBrinn | Director | Buy | $9K (4,000 @ $2.35) |
| Dec 19, 2022 | Sylvia McBrinn | Director | Buy | $31K (3,700 @ $8.33) |
| Nov 22, 2022 | Sylvia McBrinn | Director | Buy | $17K (2,000 @ $8.27) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.